Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 8/20 | 0.65 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.51 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.51 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3189263 | 0.88 | PRKCA (0.51) | PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL10026292 | 0.88 | PRKCA (0.50) | PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL6370166 | 0.88 | PRKCA (0.50) | PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL5026886 | 0.87 | PRKCA (0.60) | PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL10135101 | 0.83 | PRKCA (0.47) | PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL822220 | 0.82 | PRKCA (0.63) | PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL19300984 | 0.81 | PRKCA (0.44) | PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL8384532 | 0.80 | PRKCA (0.97) | PRKCAPRKCEPRKCQPRKCD | |
| Acetic Acid SCHEMBL8675242 | 0.80 | PRKCA (0.56) | PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL19300629 | 0.80 | PRKCA (0.56) | PRKCAPRKCEPRKCQPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2287305-B2 | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS INC (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20160053269-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | BANK OF AMERICA, N.A. | 2016-02-25 | — | — | US | disclosed |
| EP-1423406-B2 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) | SIRNA THERAPEUTICS INC (US) | 2015-11-25 | — | — | EP | disclosed |
| EP-2902406-A1 | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) | Sirna Therapeutics, Inc. (US) | 2015-08-05 | — | — | EP | disclosed |
| EP-2287305-B1 | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS INC (US) | 2015-01-07 | — | — | EP | disclosed |
| US-20140288148-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | SIRNA THERAPEUTICS INC (US) | 2014-09-25 | — | — | US | disclosed |
| US-20130018082-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | BANK OF AMERICA, N.A. | 2013-01-17 | — | — | US | disclosed |
| US-8153778-B2 | RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA) | MERCK SHARP & DOHME CORP. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8076472-B2 | RNA interference mediated inhibition of muscarinic colinergic receptor gene expression using short interfering nucleic acid (siNA) | MERCK SHARP & DOHME CORP. (US) | 2011-12-13 | — | — | US | disclosed |
| US-8013146-B2 | RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA) | MERCK SHARP & DOHME CORP. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8008472-B2 | RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA) | MERCK SHARP & DOHME CORP. (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008473-B2 | RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA) | BANK OF AMERICA, N.A. | 2011-08-30 | — | — | US | disclosed |
| US-7985853-B2 | RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA) | MERCK SHARP & DOHME CORP. (US) | 2011-07-26 | — | — | US | disclosed |
| US-7928219-B2 | chemically modified nucleic acid molecule; cancer; carcinoma, neovascularization, diabetic retinopathy, neovascular glaucoma, myopic degeneration and other proliferative diseases, restenosis and polycystic kidney disease | MERCK SHARP & DOHME CORP. (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928220-B2 | for treating ocular disease, cancer and proliferative diseases and any other disease, condition, trait or indication that can respond to the level of SDF-1 in a cell or tissue | MERCK SHARP & DOHME CORP. (US) | 2011-04-19 | — | — | US | disclosed |
| US-7855284-B2 | RNA interference mediated inhibition of checkpoint kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-20090299045-A1 | Cancer, inflammatory, respiratory, autoimmune, cardiovascular, neurological, and/or proliferative diseases | SIRNA THERAPEUTICS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090099119-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF RAS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090299045-A1 | Cancer, inflammatory, respiratory, autoimmune, cardiovascular, neurological, and/or proliferative diseases | IL15RA, IL23R, IL2RA | PRKCA 3148/4885PRKCE 3900/4885PRKCQ 3942/4885 |
| US-20130018082-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | AGO2, SNRPE, SRRT | PRKCA 2538/4885PRKCE 4524/4885PRKCQ 4317/4885 |
| US-20090099119-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF RAS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | KRAS, HRAS, NRAS | PRKCA 884/4885PRKCE 1730/4885PRKCQ 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.